What dose of Winstrol (stanozolol) do the label and trials give?

Which Winstrol tablets were supplied
ProductStrength and packStatus
Winstrol, US122 mg tablet, bottles of 100Approval listed as withdrawn in a 2010 Federal Register notice
Stromba, UK and Ireland345 mg tabletDiscontinued; Irish licence withdrawn 29/07/2003

The former US Winstrol label, as RxList reproduces it, gives a starting dose of 2 mg three times a day for hereditary angioedema and, after a favorable initial response, reduces it at intervals of one to three months to a maintenance dosage of 2 mg a day.1

Which Winstrol tablets were supplied

The table is set at the top of the page

A search of DailyMed found no Winstrol label; the text here is RxList's 2021 reproduction.1

What the label says about dose

During the dose adjusting phase, the label calls for close monitoring of the patient's response, particularly if the patient has a history of airway involvement.1 It says some patients may be managed on a 2 mg alternate-day schedule.1 The label says dosage is individualized on the basis of the patient's clinical response, and that patients are placed on the lowest possible effective dose because anabolic steroids may cause serious adverse reactions, many of them dose related.1 The only indication the label states is prophylaxis of hereditary angioedema attacks.1

A search found no separate dose for men and women. For children, the label says long-term prophylactic therapy is generally not recommended, and that safety and efficacy in children with hereditary angioedema have not been established.1

What oral trials used

A search of ClinicalTrials.gov found no registered trial of stanozolol for bodybuilding or cycle use; the trials below were in hereditary angioedema, venous disease and urticaria, apart from a lipid study in 11 male weight lifters and a study in 3 healthy young men.56 In a 2007 report by Sloane and colleagues on hereditary angioedema patients treated for 20 to 40 years, the minimal initial effective dosage was 0.5 to 2.0 mg daily; treatment-related symptoms in 10 of 21 patients subsided with a dose reduction.7

TrialDose and schedulePeopleLength
Sheffer, 19810.5 to 2 mg daily as the minimal effective dose; 4 mg a day judged unjustified for chronic therapy because of more frequent side effects827 patients with hereditary angioedema (12 male, 15 female)2 years
Sheffer, 19872 mg daily at first; after 2 months of control at that dose or at 1 mg a day, 4 mg every other day; then 2 or 1 mg every other day, with the interval widened to 1 week before stopping9Thirty-seven patients with hereditary angioedemaTo 1986, when three were on daily, 18 on alternate-day and 16 on no maintenance
Carson, 2015Oral 2 mg twice daily plus leg compression, against leg compression alone (placebo)1044 patients with lipodermatosclerosis and venous ulcers (21 active, 23 placebo)Up to 6 months
McMullin, 19915 mg or a placebo tablet, given twice daily, with graduated compression stockings for all11Sixty patients with lipodermatosclerosis6 months
Parsad, 20012 mg twice daily with cetirizine 10 mg daily, against cetirizine 10 mg daily with placebo tablets twice daily12Fifty-eight patients with chronic refractory urticaria12 weeks
Thompson, 19896 mg a day by mouth, against intramuscular testosterone enanthate 200 mg a week, in a crossover design511 male weight liftersSix weeks
Fryburg, 19970.1 mg/kg.day, route not stated63 of 5 healthy young men2 weeks

Cycle length and schedule

A search of the label and PubMed found no cycle length for stanozolol: the label and hereditary angioedema studies describe continuous treatment stepped down.

Injectable stanozolol

The only human injectable dose in these sources is stanozolol 50 mg given intramuscularly 24 hours before surgery in patients at high risk of deep vein thrombosis, cited by Blamey and colleagues (1984) as their earlier finding; in their double-blind trial of sixty patients having elective abdominal surgery, scan-positive deep vein thrombosis occurred in 12 of 29 stanozolol patients (41%) and 11 of 31 placebo patients (35%), and the authors concluded that the regimen does not prevent postoperative deep vein thrombosis.13 The only injectable strength in these sources is a US veterinary suspension of 50 milligrams (mg) of stanozolol per milliliter, for dogs, cats and horses.14 The US veterinary regulation for stanozolol, 21 CFR 522.2150, gives deep intramuscular injection at weekly intervals: in the thigh for several weeks in dogs and cats, in the gluteal region for not more than 4 weeks in horses.14 With no human injectable strength found, no mg to mL conversion is given.

Storage

The label says to store the tablets at controlled room temperature 15° to 30° C (59° to 86° F), and gives no storage after opening.1 A search found no storage source or stability data for any injectable suspension.

Frequently asked questions

Does Winstrol need mixing or water?

The label describes Winstrol tablets for oral administration.1 A search of the label and PubMed found no water or mixing instruction.

What does the label say about the liver?

The label calls for periodic liver function tests because of hepatotoxicity of 17-alpha-alkylated androgens, and for periodic serum lipid and high-density lipoprotein cholesterol tests.1

Is Winstrol a controlled substance?

The label says Winstrol is a US Schedule III controlled substance.1

References

  1. RxList. Winstrol (Anabolic steroids): Side Effects, Uses, Dosage, Interactions, Warnings. 2021. rxlist.com
  2. Federal Register. Federal Register / Vol. 75, No. 139 / Wednesday, July 21, 2010 / Notices 42455. 2010. govinfo.gov
  3. NHS dm+d. Actual Medicinal Product (AMP) - Stromba 5mg tablets - dm+d browser. dmd-browser.nhsbsa.nhs.uk
  4. HPRA. Withdrawn medicines. hpra.ie
  5. PubMed. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. 1989. pubmed.ncbi.nlm.nih.gov
  6. PubMed. Short-term modulation of the androgen milieu alters pulsatile, but not exercise- or growth hormone (GH)-releasing hormone-stimulated GH secretion in healthy men: impact of gonadal steroid and GH secretory changes on metabolic outcomes. 1997. pubmed.ncbi.nlm.nih.gov
  7. PubMed. Hereditary angioedema: Safety of long-term stanozolol therapy. 2007. pubmed.ncbi.nlm.nih.gov
  8. PubMed. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. 1981. pubmed.ncbi.nlm.nih.gov
  9. PubMed. Hereditary angioedema: a decade of management with stanozolol. 1987. pubmed.ncbi.nlm.nih.gov
  10. PubMed. Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial. 2015. pubmed.ncbi.nlm.nih.gov
  11. PubMed. Efficacy of fibrinolytic enhancement with stanozolol in the treatment of venous insufficiency. 1991. pubmed.ncbi.nlm.nih.gov
  12. PubMed. Stanozolol in chronic urticaria: a double blind, placebo controlled trial. 2001. pubmed.ncbi.nlm.nih.gov
  13. PubMed. A double-blind trial of intramuscular stanozolol in the prevention of postoperative deep vein thrombosis following elective abdominal surgery. 1984. pubmed.ncbi.nlm.nih.gov
  14. Cornell LII (21 CFR 522.2150). 21 CFR § 522.2150 - Stanozolol. law.cornell.edu